Barinthus Biotherapeutics PLC Sponsored ADR (NASDAQ:BRNS) Short Interest Down 38.8% in February

Barinthus Biotherapeutics PLC Sponsored ADR (NASDAQ:BRNS) was the target of a significant decline in short interest in the month of February. As of February 13th, there was short interest totaling 877 shares, a decline of 38.8% from the January 29th total of 1,434 shares. Currently, 0.0% of the shares of the stock are sold short. Based on an average trading volume of 50,875 shares, the days-to-cover ratio is currently 0.0 days. Based on an average trading volume of 50,875 shares, the days-to-cover ratio is currently 0.0 days. Currently, 0.0% of the shares of the stock are sold short.

Wall Street Analysts Forecast Growth

A number of research firms have weighed in on BRNS. HC Wainwright lifted their price objective on Barinthus Biotherapeutics from $3.00 to $4.00 and gave the company a “buy” rating in a report on Monday, November 17th. Weiss Ratings restated a “sell (e+)” rating on shares of Barinthus Biotherapeutics in a research report on Monday, December 22nd. Two analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus price target of $4.00.

Hedge Funds Weigh In On Barinthus Biotherapeutics

An institutional investor recently raised its position in Barinthus Biotherapeutics stock. Renaissance Technologies LLC grew its holdings in Barinthus Biotherapeutics PLC Sponsored ADR (NASDAQ:BRNS) by 115.8% in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 143,100 shares of the company’s stock after buying an additional 76,800 shares during the quarter. Renaissance Technologies LLC owned approximately 0.35% of Barinthus Biotherapeutics worth $100,000 at the end of the most recent reporting period. 25.20% of the stock is owned by institutional investors.

Barinthus Biotherapeutics Trading Up 0.2%

NASDAQ:BRNS opened at $0.58 on Friday. The stock has a market capitalization of $23.85 million, a P/E ratio of -0.31 and a beta of -0.66. Barinthus Biotherapeutics has a 1 year low of $0.56 and a 1 year high of $2.92. The firm has a 50 day moving average of $0.69 and a 200-day moving average of $0.95.

About Barinthus Biotherapeutics

Barinthus Biotherapeutics plc, a clinical-stage biopharmaceutical company, engages in development of novel T cell immunotherapeutic candidates designed to guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. The company's development pipeline includes VTP-300, an immunotherapeutic candidate under phase 2 studies as a potential component of a functional cure for chronic hepatitis B virus (HBV) infection; VTP-200, a non-surgical product candidate under phase 2 studies for treating persistent high-risk human papillomavirus (HPV) infection; VTP-1000, an autoimmune preclinical candidate designed to treat patients with celiac disease; VTP-1100 product candidate to target HPV16+ cancers; and VTP-850/850, a second-generation immunotherapeutic candidate under phase 2 studies to treat recurrent prostate cancer.